• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    ABSTRACT A dry powder drug inhaler (100, 600, 700) comprising: a housing (101, 601, 701), said housing comprising at least one air inlet (102, 602, 702) and at least one airoutlet (103, 603, 703), is provided. The inhaler further comprises a container (104, 604,704) comprising a dry powder drug, wherein, upon inhalation by a user at said at leastone outlet (103, 603, 703), an airflow from the at least one air inlet (102, 602, 702) tothe at least one outlet (103, 603, 703) will convey said dry powder drug if aspiration ofthe user is perforrned after revealing said dry powder drug from the container (104, 604,704). A strip (105, 605, 705), said strip (105, 605, 705) forrning a part of said container(104, 604, 704) and occluding at least one of said at least one air outlet (103, 603, 703),is arranged on said housing, such that removal of the strip (105, 605, 705) from thehousing (101, 601, 701) reveals said dry powder drug and said at least one of said atleast one air outlet (103, 603, 703). To be published with Fig. 1
    公开号:SE1351577A1
    申请号:SE1351577
    申请日:2013-12-23
    公开日:2015-06-24
    发明作者:Johan Lundgren；Lars Arvidsson；Mårten Rittfeldt；Orest Lastow；Carl Forslund
    申请人:Iconovo Ab；
    IPC主号:
    专利说明:

    SINGLE DOSE DRY POWDER INHALER Field of the Invention This invention pertains in general to the field of medicament inhalers, andmore particularly to dry powder inhalers, and such dry powder inhalers for one doseadministration. The inhaler comprises at least one air inlet and at least one air outlet,and a container comprising a pre-filled dry powder drug, the inhaler having an airflowthere through from the at least one air inlet to the at least one outlet during inhalation bya user at said at least one outlet, which airflow will convey said dry powder drug ifinhalation by the user is performed after dispersing said dry powder drug from the container.
    Background of the Invention In the pharrnaceutical field, with respect to treatment of respiratory and/orother diseases, inhalers have been widely used. Numerous drugs, medications and othersubstances are inhaled into the lungs for rapid absorption in the blood stream and forlocal action in the lung with such inhalers.
    Inhaled drugs fall into two main categories, in form of liquids, includingsuspensions, and powders. The choice of category depends on the characteristics of thedrugs, medications, etc., to be inhaled.
    The most common type of inhaler is the pressurized metered-dose inhaler. Inthis type of inhaler medication is most commonly stored in solution in a pressurizedcanister that contains a propellant, although it may also be a suspension. The canister isattached to a plastic, hand-operated actuator. On activation, the metered-dose inhalerreleases a fixed dose of medication in aerosol form.
    Another kind of inhaler is a nebulizer, which supply medication as an aerosolcreated from an aqueous forrnulation.
    The kind referred to herein is yet another type, in form of a dry powder inhaler,and specifically a one dose dry powder inhaler. A dry powder inhaler releases a meteredor device-metered dose of powdered medication that is inhaled through the inhaler.
    Dry powder inhalers need to deliver a particle size that is predominantly below 5 microns, and preferably between l micron and 3.3 microns, for maximum effectiveness. Such small particles are, however, very cohesive due to high surfaceenergy. Agglomeration may be worsened by moisture, whereby it is specificallyappropriate to keep the metered dose protected from moisture in a container, which isopened, such that the drug/medication therein is revealed, shortly before inhalation. Inthis context, reveal means that the drug/medication is uncovered, such that it may exitthe container. Agglomeration of small particles is a problem which results in the activeparticles leaving the inhaler as large agglomerates.
    WO200800802l relates to an inhalation system for the administration of a drugin the form of dry powder by inhalation through an airflow path. The system comprisesa delivery device, having a mouthpiece through which the powder is inhaled, a dosecassette comprising at least one drug cavity for each dose, comprising a dose to bedelivered.
    WO20l0024759 relates to a an inhaler. The inhaler comprises a base having atleast one foil sealed cavity containing medicament. A separating element is attached tothe foil for separating the foil from the cavity.
    WO20l002l589 relates to an inhaler in which an outlet cover is connected to amovable actuator portion located upstream of a sealed medicament-containing cavity.As the outlet cover is removed from the outlet, the actuator portion moves downstreamof the cavity and a sealing foil becomes separated from the cavity.
    One dose dry powder inhalers, of these kinds, are provided with one metereddose, and this kind of inhaler may for example be used for vaccinations, clinical trials oremergency healthcare, wherein the user not is a day to day user, and the inhalertherefore goes to waste after its only use. These kind of inhalers are, for economicalreasons, kept to the minimum with regard to pieces and parts, since the consumption ishigh and lifetime is low. Therefore, they are norrnally provided with unprotectedinlets/outlets, and perhaps with a cover cap applied over, for example, the outlet. In use,such as in emergencies, the user needs to remove the cap, if there is one, and thereafterreveal the drug. If there is no cap, there is a risk that (i) the inlet or outlet has been fullyor partly blocked before use, whereby the delivery of the inhaled drug is impaired andthe well being of the patient is jeopardized,(ii) foreign particles entering the devicethrough the outlet or inlet before usage leading to a risk of inhaling foreign particlesputting the patient at a risk and (iii) the outlet being soiled or contaminated and beingunhygienic. In view of these drawbacks and limitations of the prior art, what is neededis a dry powder inhaler device in which effective and satisfactory dispersion of the dry powder is obtained, while simultaneously facilitating opening of the drug cavity and omitting unnecessary usage steps and handling, and minimizing the risk of clogging and/or soiling of inlets and outlets.
    Summary of the Invention Accordingly, the present invention preferably seeks to mitigate, alleviate oreliminate one or more of the above-identified deficiencies in the art and disadvantagessingly or in any combination and solves at least the above mentioned problems byproviding a dry powder drug inhaler comprising: a housing, said housing comprising atleast one air inlet and at least one air outlet, and a container comprising a dry powderdrug, wherein, upon inhalation by a user at said at least one outlet, an airflow from theat least one air inlet to the at least one outlet will convey said dry powder drug ifinhalation by the user is performed after dispersing said dry powder drug from thecontainer; and a strip, said strip forrning a part of said container and occluding at leastone of said at least one air outlet, such that removal of the strip from the housing revealssaid dry powder drug and said at least one of said at least one air outlet.
    Further advantageous embodiments are disclosed in the appended and dependent patent claims.
    Brief Description of the Drawings These and other aspects, features and advantages of which the invention iscapable of will be apparent and elucidated from the following description ofembodiments of the present invention, reference being made to the accompanyingdrawings, in which Fig. l is a perspective view from an outlet end of an inhaler according to anembodiment of the present invention; Fig. 2 is a perspective view from an inlet end of an inhaler according to anembodiment of the present invention; Fig. 3 is a top view of an inhaler according to an embodiment of the presentinvention; Fig. 4 is a cross sectional view along a longitudinal axis of an inhaler according to an embodiment of the present invention; Fig. 5 is a side and close up View of a container in an inhaler according to anembodiment of the present inVention; Fig. 6 is a cross sectional View along a longitudinal axis of an inhaler accordingto an embodiment of the present inVention; and Fig. 7 is a cross sectional View along a longitudinal axis of an inhaler according to an embodiment of the present inVention.
    Description of embodiments The following description focuses on an embodiment of the present inVentionapplicable to a medicament inhaler, and in particular to a dry powder drug inhaler for aone dose administration. However, it will be appreciated that the inVention is not limitedto this application but may be applied to many other inhalers having an inlet and anoutlet, as well as a medicament container.
    Figs. 1 to 5 illustrate a dry powder drug inhaler 100. The dry powder druginhaler 100 comprises a housing 101. The housing 101 comprises an air inlet 102 and anair outlet 103. The outlet 103 is arranged at a first end of the housing 101, while theinlet 102 is arranged at an opposite second end of the housing 101.
    The number of inlets and outlets may be different from what is disclosed inFigs. 1 to 5. The number of inlets may for example be adjusted in accordance withneeds and specific inhaler design, such that a number of smaller inlets, for reducingpressure fall oVer the inhaler, are arranged circumferentially of the housing 101. This isnot shown. In a corresponding manner the number of air outlets may be adjusted inaccordance with needs and specific inhaler design.
    The housing 101 may be manufactured in a suitable material, such as injectionmoldable plastics, such as therrnoplastics.
    The inhaler 100 further comprises a ccontainer 104, arranged in the housing101. The container 104 comprises a dry powder drug, such as in the form of a pre-filleddrug containing container 104. Upon inhalation by a user at the outlet 103, an airflowfrom the inlet 102 to the outlet 103 will convey said dry powder drug if inhalation bythe user is performed after revealing, i.e. uncovering, the dry powder drug in thecontainer 104.
    The container 104 is preferably arranged close to the first end of the housing 101, i.e. close to the inlet 102. In this way, the drug may be affected directly of air entering the housing 101, such that the drug will have an increased amount of time to bedistributed in the air stream before exiting the inhaler 100 at the outlet 103. This resultsin an improved drug/ air profile, increasing the possibility of drug entering an increasedarea/volume of the lungs of the user.
    A strip 105 is arranged on the housing 101. The strip 105 forms a part of thecontainer 104, such that removal of the strip 105 will reveal the drug in the container104. Also the strip 105 occludes the outlet 103, such that removal of the strip 105 fromthe housing 101 reveals the outlet 103. In this way the strip 105 forms a protective sheetat the outlet 103, such that the potential user will have a decreased risk of clogging theoutlet or getting the outlet 103 dirty during keeping or storage, bearing in mind that theuser shall inhale on this outlet 103 during use. The strip 105 also occludes the inlet 102,such that the strip 105 forms a protective sheet also at the inlet 102, such that thepotential user will have a decreased risk of clogging also the inlet 102 or get the inlet102 dirty during keeping or storage.
    The strip 105 has a first end 106 in the vicinity of the outlet 103. This first end106 allows for easy access of the strip 105, by for example providing it with a pull tab107. Furthermore, the strip runs longitudinally of said housing 101 to said container104, optionally via the inlet 102. The strip 105 runs on an outer surface of said housing101 from the outlet 103 to the container 104, optionally via the inlet 102. The strip 105is arranged double folded at said container 104, such that it attaches to the container 104centrally. This means that the strip attaches to the container on a side of the containerfacing away from the second end of the housing 101, i.e. being closer to the center ofthe housing along a longitudinal axis of the housing 101 and thus the inhaler 100. In thisway, when pulling the strip away from the housing 101, the strip 105 will tear thecontainer 104 in a direction from the centre of the housing 101 towards the second endof the housing 101. Then, the tearing, i.e. the breakage, of the container 104 will revealthe dry powder drug. To facilitate rupture/tearing of the container 104, the containercomprises the form of a blister package, wherein the strip 105 attaches to/ forrns a part ofthe container 104. In other words, the container 104 comprises a base portion 104a, witha cavity 104b for receiving the drug. Additionally, the container 104 comprises a cover104c arranged over the container cavity 104b and the drug, and the cover 104c is a partof, i.e. attaches to or is monolithically formed with, the strip 105.
    The strip 107 and the container 104 may for example be manufactured in asuitable material for enclosing openings and cavities, and specif1cally cavities for holding moisture sensitive drugs. One such suitable material is an aluminum foil, such as an aluminum foil laminated with a plastic. It is not necessary that also the strip 107 ismade of a moisture barrier of this kind, but for facilitating manufacturing the same foilmay be used for the strip 107 as for the container 104.
    Before use, the user will hence grab the pull tab 107; pull the strip 105 over theoutlet 103; then proceed with turning the inhaler 100 or pulling the strip 105 from belowalso oVer the inlet 102; to finally pull the strip 105 away from the housing 101 to breakthe container 104 and reVeal the drug. After this, the user will bring the outlet 103 tohis/her mouth, and inhale, such that the drug will disperse into the air stream and beconVeyed by the air stream into the respiratory tract of the user.
    In an altemative embodiment, in accordance with Fig. 6, the strip 605 runswithin the housing 601 of the inhaler 600. In this embodiment the pull tab 607 ispositioned at the second end of the housing 601, i.e. in the Vicinity of the inlet 602. Thestrip 605 then also has its first end 606 in said position, where after the strip continuesto occlude the inlet 602, then occluding the outlet 603, to f1nally attach to the container604. Thus, before use, the user will hence grab the pull tab 607; pull the strip 605 out ofthe inlet 602; then proceed with pulling the tab 607 and the strip away from the inhaler600 to reVeal the outlet 603 from within; continuing pulling the tab 607 and the strip605 away from the inhaler 600 to break the container 604 and reVeal the drug. Afterthis, the user will bring the outlet 603 to his/her mouth, and inhale, such that the drugwill spread in the air stream and be conVeyed by the air stream into the respiratory tractof the user. This embodiment allows for reVealing of the inlet 602, the outlet 603, andthe drug in a one directed motion, which may be benef1cial if the user for example has adecreased dexterity.
    In yet an altemative embodiment, in accordance with Fig. 7, the pull tab 707 isagain positioned at the second end of the inhaler 700. The strip 705 continues from thepull tab in a bifurcation; one part of the strip continuing oVer the container 704, to attachthereto centrally of the housing 701; and another part of the strip 705 continuing toocclude the inlet 702, further along the outside of the housing 701 to the first end tothere occlude the outlet 703. Hence, before use, the user will hence grab the pull tab707; pull the strip 705 out of the inlet 702; then proceed with pulling the tab 707 and thestrip away from the inhaler 700 to break the container 704 to reVeal the drug; thenproceed with tuming the inhaler 700 or pulling the strip 705 from below also over theoutlet 703. After this, the user will bring the outlet 703 to his/her mouth, and inhale,such that the drug will spread in the air stream and be conVeyed by the air stream intothe respiratory tract of the user.
    Although, the present invention has been described above With reference tospecific embodiments, it is not intended to be limited to the specific forrn set forthherein. Rather, the invention is limited only by the accompanying claims.
    In the claims, the terrn “comprises/comprising” does not exclude the presence of other elements or steps. Furthermore, although individually listed, a plurality of means, elements or method steps may be implemented by eg. a single unit or processor.
    Additionally, although individual features may be included in different claims, thesemay possibly advantageously be combined, and the inclusion in different claims doesnot imply that a combination of features is not feasible and/or advantageous. Inaddition, singular references do not exclude a plurality. The terms “a”, “an”, “f1rst”,“second” etc do not preclude a plurality. Reference signs in the claims are providedmerely as a clarifying example and shall not be construed as limiting the scope of the claims in any Way.
    权利要求:
    Claims (10)
    [1] 1. A dry powder inha1er (100, 600, 700) comprising: a housing (101, 601,701), said housing comprising at 1east one air in1et (102, 602, 702) and at least one airout1et (103, 603, 703), and a container (104, 604, 704) comprising a dry powder drug,wherein, upon inha1ation by a user at said at 1east one out1et (103, 603, 703), an airflowfrom the at 1east one air in1et (102, 602, 702) to the at 1east one out1et (103, 603, 703)wi11 convey said dry powder drug if inha1ation by the user is perforrned after revea1ingsaid dry powder drug in the container (104, 604, 704); and a strip (105, 605, 705), saidstrip (105, 605, 705) forrning a part of said container (104, 604, 704) and occ1uding at1east one of said at 1east one air out1et (103, 603, 703), such that removal of the strip(105, 605, 705) from the housing (101, 601, 701) revea1s said dry powder drug and saidat 1east one of said at 1east one air out1et (103, 603, 703).
    [2] 2. The dry powder drug inha1er (100, 600, 700) according to c1aim 1,wherein said strip (105, 605, 705) occ1udes at 1east one of said at 1east one air in1et (102,602, 702).
    [3] 3. The dry powder drug inha1er (100) according to c1aim 1 or 2, whereinsaid strip (105) has a first end (106) in the vicinity of said at 1east one of said at 1eastone air out1et (103), and runs 1ongitudina11y of said housing (101) to said container(104).
    [4] 4. The dry powder drug inha1er (100) according to c1aim 3, wherein saidstrip (105) has a first end (106) in the vicinity of said at 1east one of said at 1east one airout1et (103), and runs 1ongitudina11y of said housing (101) to cover said at 1east one of said at 1east one air in1et (102), where after it proceeds to said container (104).
    [5] 5. The dry powder drug inha1er (600) according to c1aim 1 or 2, whereinsaid strip (605) runs from said at 1east one of said at 1east one air in1et (602) within saidhousing (601) to cover said at 1east one of said at 1east one air out1et (603), said strip (605) then running to said container (604).
    [6] 6. The dry powder drug inha1er (700) according to c1aim 1 or 2, whereinsaid strip (705) runs from said at 1east one of said at 1east one air in1et (702), bifurcating into one part of said strip (705) continuing over said container (704) to attach thereto, and another part of said strip (705) continuing along the outside of said housing (701) to cover said at least one of said at least one air outlet (603).
    [7] 7. The dry powder drug inhaler (100, 600, 700) according to any of thepreceding c1ain1s, wherein said strip (105, 605, 705) is provided with a pull tab (107,607, 707) at said first end.
    [8] 8. The dry powder drug inhaler (100, 600, 700) according to any of thepreceding c1ain1s, wherein the strip (105, 605, 705) is arranged double folded at saidcontainer (104, 604, 704) coniprising a dry powder drug, such that it attaches to thecontainer (104, 604, 704) centrally, such that pulling the strip (105, 605, 705) awayfrom the housing (101, 601, 701) will reveal the dry powder drug.
    [9] 9. The dry powder drug inhaler (100, 600, 700) according to any of thepreceding clain1s, wherein the container (104) con1prises a base portion (104a), with acavity (104b) for receiving said dry powder drug, and a cover (104c) arranged over saidcavity (104b) and said dry powder drug wherein said cover (104c) is a part of said strip(105).
    [10] 10. The dry powder drug inhaler (100, 600, 700) according to any of the preceding clain1s, wherein the dry powder inhaler is a single dose dry powder inhaler.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6679255B2|2004-01-20|Inhaling device for dispensing powdered medicaments contained in a capsule through the respiratory tract
    KR101547502B1|2015-08-26|Nasal delivery devices
    FI111444B|2003-07-31|Disposable inhaler
    JP4921549B2|2012-04-25|Improvement of dry powder inhaler
    ES2292240T3|2008-03-01|INHALATION DEVICE FOR UNIT DOSE.
    FI105776B|2000-10-13|Disposable inhaler
    JP2008501472A|2008-01-24|Dry powder inhaler
    US5239991A|1993-08-31|Disposable powder medicament inhalation device with peel-off cover
    SE538667C2|2016-10-11|Enkeldostorrpulverinhalator
    JP2927506B2|1999-07-28|Disposable medicine inhaler
    US6772755B2|2004-08-10|Pen-shaped inhaling device for dispersing powdered medicaments through the respiratory tract
    JP2021090814A|2021-06-17|Single dose dry powder inhaler
    JP5394440B2|2014-01-22|Inhaler
    US20180117275A1|2018-05-03|Aroma Emitting Pacifier
    CN106255524B|2020-03-24|Inhalation device for inhaling powder
    EP1177805A1|2002-02-06|Powder inhaler
    BR112020000889A2|2020-07-21|single dose powder inhaler
    RU2418609C1|2011-05-20|Filter for nasal cavity
    BR112019021035A2|2020-05-12|LOW COST SINGLE USE POWDER INHALER
    CN107921232A|2018-04-17|The clip nasal cavity air wetting being used together with supplemental oxygen and nosebleed epistaxis preventing mean and method
    JP2020520686A|2020-07-16|Inhaler using a synthetic jet
    WO2018072665A1|2018-04-26|Multi-cavity atomizing apparatus
    同族专利:
    公开号 | 公开日
    WO2015097034A1|2015-07-02|
    SE538667C2|2016-10-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB8914223D0|1989-06-21|1989-08-09|Fisons Plc|Medicament container|
    US5042472A|1990-10-15|1991-08-27|Merck & Co., Inc.|Powder inhaler device|
    SE9700421D0|1997-02-07|1997-02-07|Astra Ab|Single dose inhalation I|
    SE9700422D0|1997-02-07|1997-02-07|Astra Ab|Single dose inhaler II|
    AU2003267809A1|2002-06-07|2003-12-22|Sun Pharmaceutical Industries Limited|Powder inhaler|
    GB0215904D0|2002-07-09|2002-08-21|Team Holdings Uk Ltd|Drug delivery system and method|
    EP1488819A1|2003-06-16|2004-12-22|Rijksuniversiteit te Groningen|Dry powder inhaler and method for pulmonary inhalation of dry powder|
    GB0520794D0|2005-10-12|2005-11-23|Innovata Biomed Ltd|Inhaler|
    EP2747815B1|2011-09-07|2017-11-29|Concentrx Pharmaceuticals, Inc.|Dry powder inhalation device|WO2015168572A2|2014-05-02|2015-11-05|Manta Devices, Llc|Delivery device and related methods|
    SE539111C2|2015-06-03|2017-04-11|Iconovo Ab|Single dose dry powder inhaler|
    WO2018183528A1|2017-03-28|2018-10-04|Concentrx Pharmaceuticals, Inc.|Devices and methods for delivering dry powder medicaments|
    US20200230332A1|2017-09-19|2020-07-23|Iconovo Ab|Dry powder inhaler comprising a casing with a first casing portion and a second casing portion|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE1351577A|SE538667C2|2013-12-23|2013-12-23|Enkeldostorrpulverinhalator|SE1351577A| SE538667C2|2013-12-23|2013-12-23|Enkeldostorrpulverinhalator|
    PCT/EP2014/078217| WO2015097034A1|2013-12-23|2014-12-17|Single dose dry powder inhaler|
    [返回顶部]